Physician profile
Emily Dell
NPI 1538575709
$4,368.62
in general payments reported to CMS, 2019-2025
27 companies · $692 in 2025
The $692 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,108 · 2020: $430 · 2021: $258 · 2022: $497 · 2023: $749 · 2024: $633 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,074.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $741.91 | 2019-2025 | Skyrizi, Botox |
| Novartis Pharmaceuticals Corporation | $694.83 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $372.00 | 2019-2025 | Dupixent, Libtayo |
| Allergan, INC. | $355.95 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $355.13 | 2019-2025 | Ilumya |
| Amgen INC. | $295.07 | 2019-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $211.44 | 2019-2025 | Tremfya |
| Genentech USA, INC. | $165.96 | 2019-2021 | |
| Ucb, INC. | $156.85 | 2019-2025 | Bimzelx |
| Lilly USA, LLC | $116.87 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $105.51 | 2019-2023 | |
| Incyte Corporation | $101.01 | 2023-2024 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $98.00 | 2022-2025 | Sotyktu |
| Celgene Corporation | $91.82 | 2019 | |
| Biofrontera INC. | $82.29 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $75.81 | 2021-2023 | |
| Dermavant Sciences, INC. | $68.37 | 2023-2024 | Vtama |
| Mayne Pharma Commercial LLC | $63.21 | 2019-2023 | |
| Galderma Laboratories, L.P. | $42.82 | 2022-2023 | |
| Revance Therapeutics, INC. | $37.95 | 2024 | Daxxify |
| Arcutis Biotherapeutics, INC. | $34.83 | 2025 | Zoryve |
| Biowound Solutions, INC. | $28.55 | 2025 | Bio-Connekt |
| Tactile Systems Technology INC | $20.12 | 2023 | Flexitouch Plus, Entre Plus |
| Almirall LLC | $14.02 | 2023 | Seysara |
| Leo Pharma INC. | $13.58 | 2023 | Adbry |
| Organon LLC | $13.53 | 2025 | |
| Dermira, INC. | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Dell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.